Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Research and Development Expenses: $39.1 million for Q3 2024, down from $51.1 million in Q3 2023. Net Loss: $6.9 million or $0.26 per diluted share for Q3 2024, compared to $16.2 million or $0.61 per diluted share for Q3 2023. Cash, Cash Equivalents, and Restricted Cash: $294.1 million as of September 30, 2024. Commercial Milestone: $25 million received with the first sale of KOSTAIVE in Japan. Cash Runway: Expected to extend into Q1 of fiscal year 2027. Warning! GuruFocus has detected 6 Warning Signs with ARCT. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Arcturus Therapeutics Holdings Inc ( NASDAQ:ARCT ) successfully launched its COVID-19 vaccine, KOSTAIVE, in Japan, marking the company's first commercial product. The company received a $25 million commercial milestone from the first sale of KOSTAIVE in Japan. Positive Phase 3 results were announced for ARCT-2303, demonstratin
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.MarketBeat
- Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness Wire
ARCT
Earnings
- 11/7/24 - Beat
ARCT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- ARCT's page on the SEC website